The NRG4 gene is a member of a family of four genes that encode a class of epidermal growth factors. This gene has been reported to express a protein designated here as NRG4A1. We describe here a novel splice variant of the NRG4 gene, NRG4A2, which encodes a C-terminal region containing a predicted type I PDZ-binding peptide. Both NRG4A1 and NRG4A2 were shown to be expressed on the cell surface, as expected by the presence of a predicted transmembrane sequence, and were modified at a single N-linked glycosylation site in the extracellular domain. Significant stabilization of expression of both proteins was seen in the presence of the proteosome inhibitor MG-132 suggesting that they are normally degraded by this system. N-terminal cleavage was inhibited in both isotypes by the broad-spectrum matrix metalloproteinase inhibitor, galardin (GM 6001). A glycosylated, secreted form of NRG4A1 was detected in the cell medium which showed biological activity in two assays, phosphorylation of the HER4 receptor and stimulation of neurite formation in PC-12 cells stably expressing HER4. Transfection and expression of green fluorescent protein-tagged proteins and immunofluorescent staining with specific anti-peptide antibodies showed that NRG4A1 is localized to membrane ruffles, while NRG4A2 has a more punctate membrane distribution.
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The neuregulins (NRGs) are a family of growth factors that possess a wide range of possible activities including promoting cell growth, differentiation, migration, apoptosis and adhesion (Falls, 2003) . There are four mammalian NRG genes (NRG1-4) each of which can encode a homologous epidermal growth factor (EGF)-like domain which is the minimum requirement for the stimulation of ErbB receptor tyrosine kinases. NRGs 1 and 2 interact with ErbB3 and ErbB4, while NRG3 and NRG4 are reported to bind only ErbB4 (Hobbs et al., 2002) . Each NRG gene has a characteristic pattern of expression in normal tissues, NRG1-3 are all expressed in the nervous system, while NRG4 was detected in a limited number of adult tissues but not the brain (Harari et al., 1999) . To date, only one product has been reported for the NRG4 gene which encodes a 115 amino acid transmembrane protein containing an EGF domain homologous to the other NRGs, but outside this region shares little sequence homology with the other NRGs (Buonanno and Fishbach, 2001) . It is probable that NRG4 is synthesized as a pro-form, similar to other ErbB ligands, with which it shares structural similarity. Hydropathy plot analysis predicts a single transmembrane region between amino acids 64 and 83 and sequence analysis predicts an EGF domain at the immediate N terminus of the protein (Harari et al., 1999) which contains a single N-linked glycosylation site (NYT) located at residue 39 between the fifth and sixth cysteine, a feature found at the N terminus of the EGF domain of NRG2 (Higashiyama et al., 1997) but not in any of the other EGF receptor ligands. This is followed by a relatively short serine-rich region, representing a putative proteolytic site. Inspection of the sequence of NRG4 shows that this peptide lacks both an N-terminal hydrophobic signal sequence and a run of apolar residues, which are required for correct insertion into the membrane. It is unclear therefore how NRG4 is inserted into the membrane and how the ectodomain is shed (as is the case for some NRG1 isoforms, Wakatsuki et al., 2004) to produce an ErbB4 receptoractivating ligand. Harari et al. (1999) who reported the first sequence of NRG4 showed that a refolded peptide representing the EGF domain of mouse NRG4 stimulated the phosphorylation of HER4 and the downstream second messenger protein mitogen-activated protein kinase.
Extensive alternative mRNA splicing and the use of at least six sites of initiation of transcription in NRG1 allows the production of more than 15 variants (Harrison and Law, 2006) . NRG2 is also alternatively spliced to produce a and b variants (Yamada et al., 2000) , and recently isoforms of NRG3 have been described (Carteron et al., 2006) . There have previously been no reports of NRG4 splice variants. In previous work on NRG4 expression in breast cancer, we observed using reverse transcription (RT)-PCR additional NRG4 mRNA products (Dunn et al., 2004) . Here we characterize two of these variants which both posses transmembrane sequences; the previously described NRG4 variant described by Harari et al. (1999) which we designate NRG4A1 and a novel 270 bp transcript designated as NRG4A2.
Reverse transcription (RT)-PCR on the breast cancer cell line ZR 75 using full-length NRG4A1 primers revealed two NRG4 species: one of 345 bp (NRG4A1 accession number BC017568) and the other 270 bp (NRG4A2 accession number AM392364) (Figure 1a ). When sequenced, the second product showed 100% identity to NRG4A1 from amino acids 1 to 85 and then six unique C-terminal amino acids (CGNTCM), which are predicted to be intracellular (Figures 1b and c) . The final four amino acids (NTCM) are predicted to encode a type I PDZ-binding peptide (see Harris and Lim, 2001 for criteria).
Transient transfection of full-length C-terminally tagged green fluorescent protein (GFP) fusions of NRG4A1 and A2 transcripts into Cos-7 cells and immunoblotting with an anti-GFP antibody revealed three molecular weight species for each NRG4 isoform only in the presence of the proteosome inhibitor MG-132 ( Figure 2a ) (an additional band at approximately 25 kDa, which runs at the same position as GFP expressed alone (Figure 2a , lane 7), may represent GFP produced by proteolyic cleavage). It has also been reported that the expression of a splice variant of NRG3 (hFBNRG3) which is found in human foetal brain is enhanced in the presence of proteosome inhibitors, and the authors suggest that proteosomal degradation of this protein may be indirectly mediated by ubiquitination (Carteron et al., 2006) . Both NRG4 isoforms contain lysine residues (NRG4A1/A2 K14, K57 and additionally NRG4A1 K83), which might be targets for ubiquitination (although only K83 is predicted to be intracellular). The high molecular weight smears seen in Figure 2b may represent ubiquitinated NRG4A proteins, but this will require further investigation. For each splice variant, a band of the correct predicted size of the recombinant protein (NRG4A1, 39.5 kDa and NRG4A2, 36.9 kDa) was observed as well as a fainter doublet of higher molecular weight. The anti-127 antibody, raised using a synthetic peptide from the Identification and sequence alignment of NRG4A2 from ZR 75 breast cancer cell line. ZR 75 cells were cultured to 80% confluency in DMEM, 10% FCS (Gibco, Paisley, UK), 2 mM L-glutamine, 50 mg/ml penicillin and 50 mg/ml streptomycin. RNA (RNeasy Mini Kit and QIAshredder, Qiagen, West Sussex, UK) was reverse-transcribed and RT-PCR was carried out using (a) NRG4A1 (lane 1) and NRG4A2 (lane 2) specific primers. Forward primer for both isotypes 5 0 -NRG4 F 5 0 -CACCATGCC AACAGATCACGAAGAGCC-3 0 ; the reverse primer for NRG4A1; 5 0 -GTGTTGTTCATGACTGTGGTGG-3 0 ; NRG4A2; 5 0 -CTACATGCATGTGTTACCACACC-3 0 . The PCR products were separated using 3% agarose gel electrophoresis, the band(s) excised and cleaned (QIAquick gel extraction kit, Qiagen). (b) Sequencing of the PCR products (Lark Technologies, Essex, UK) allowed alignment of NRG4A1and NRG4A2. An asterisk indicates where the two sequences diverge. (c) Alignment of the translated transcripts showing the position of the peptides used to raise the N-terminal pan anti-NRG4 rabbit antibody (anti 127), the C-terminal NRG4A1-specific rabbit antibody (anti-128). The predicted transmembrane region, the N-linked glycosylation site, the predicted PDZ domain and the peptides use for antibody production are underlined.
Characterization of membrane-associated NRG4 variants NVL Hayes et al common N-terminal sequence of the isoforms, (Figure 1c ) detected the lower band for each isotype reproducibly but the higher molecular weight doublet inconsistently between different experiments (Figure 2b ) which may indicate variable proteolytic or other posttranslational modification occurs. The NRGA1-specific antibody, anti-128 (Figure 1c ), only detected NRG4A1 as expected (Figure 2c ). The amino acid sequence of the NRG4 isoforms indicates that a single potential glycosylation site is present (Figure 1c) . To establish whether any of the observed bands represented glycosylated species, the proteins were treated with PNGase F and a shift of the higher band in the doublet to the lower band in the doublet confirmed deglycosylation had occurred in both the NRG4 isoforms (Figure 2d ). It has been reported that some NRGs in cultured cells are cleaved by the matrix metalloproteases ADAM 17 and ADAM 19 (Montero et al., 2000; Shirakabe et al., 2001) . We therefore treated the cells with galardin, a broadspectrum metalloprotease inhibitor that inhibits TACE/ADAM type proteases, and there was an indication that in the presence of the inhibitor there was stabilization of both the NRG4 A type isoforms (Figure 2e) .
We next determined whether the variants were expressed on the cell membrane, and whether the N terminus was orientated on the extracellular surface. Sequence analysis using the criteria of von Heijne (2006) predicted that these variants would be type I transmembrane proteins with the N terminus exposed on the extracellular space. Cos-7 cells were transfected with the GFP-tagged fusion, fixed and either permeabilized with detergent or left unpermeabilized and then stained with the anti-127 antibody. Cell-surface expression was seen in the GFP-tagged images, but the anti-127 antibody only detected the protein in permeabilized but not unpermeabilized cells. We hypothesized that this might be due to rapid shedding of the extracellular domain by one of the TACE/ADAM type proteases. The cells were therefore treated with galardin and under these conditions, the N-terminal antibody now gave a strong signal in unpermeabilized cells indicating that galardin allowed the accumulation of uncleaved protein and that the N terminus was exposed on the cell surface (Figure 3a) .
The two variants differed only in their intracellular domains and, as NRG4A2 possessed a PDZ-binding sequence, we assessed whether they might have different plasma cell membrane localizations. Transient transfections of Cos-7 cells with constructs of NRG4A1 and NRG4A2 lacking the C-terminal GFP tag (so as not to mask the PDZ-binding domain) ( Figure 3b ) were carried out in the presence of galardin and the proteins detected using immunofluorescent staining (Roobol et al., 1995) using the anti-127 antibody on unpermeabilized cells. At 24 h post-transfection NRGA1 was localized to membrane ruffles, while NRG4A2 had a fine uniform punctuate appearance (Figure 3b, lower panel) . A similar membrane distribution was observed using the GFP-tagged constructs of the two NRG4 variants (Figure 3b) , which demonstrate that the GFP tag does not alter the membrane localization of either variant.
The data presented above (Figures 2 and 3) suggested that a glycosylated, extracellular fragment containing an EGF domain would be present in the cell growth medium. To test this, conditioned media from Cos-7 cells transiently transfected with NRG4A1-GFP was collected, concentrated, loaded onto a Concanavalin A (Con A) column, and bound glycoproteins were eluted. This eluate was added to NIH3T3 HER4 cells, and western blotting with anti-phosphotyrosine antibodies revealed a strong band at the predicted molecular weight of the ErbB4 receptor not present in the mock-treated cell lysate (Figure 4a, lanes 1-3) . As a further control, refolded and oxidized NRG4 peptide (as described by Figure 2 Identification, deglycosylation and protease inhibition of NRG4A1/A2 transcripts. Both NRG4A1 and NRG4A2 full-length PCR products were directionally subcloned into pEGFP-N1 (Clontech, Saint-German-En-Laye, France) using SacII/KpnI sites in frame with a C-terminal GFP tag. Cos-7 cells were transfected (Fugene 6, Roche, West Sussex, UK) in 2 cm dishes with 0.2 mg NRG4 A1 GFP (a, lanes 2-3), NRG4A2 GFP (a, lanes 5-6) or GFP only (a, lane 7) for 24 h and 20 mM of the proteosome inhibitor MG-132 (Sigma, Dorset, UK) was added (lanes 1, 3, 4 and 6) for 18 h before lysis. The cells were lysed by directly adding 2 Â Laemelli sample buffer, and 15% SDS-PAGE was carried out on the samples. Immunoblotting onto nitrocellulose (Amersham, Bucks, UK) and probing with (a) 3E1 antimouse GFP monoclonal antibody (b) rabbit anti-127 (NRG4 pan-specific antibody) and (c) rabbit anti-128 (NRG4A1-specific) was carried out. For deglycosylation, cells were lysed (50 mM Tris, 0.15 M NaCl, 1% Triton X-100, 5 mM EDTA, plus protease inhibitors) and proteins denatured by the addition of 0.5% SDS, 40 mM DTT at 1001C for 10 min. 50 mM NaHPO 4 2H 2 O 10%, pH 7.5 and 10% Nonidet was added to the samples followed by 2000 U PNGase F (New England BioLabs, Herts, UK) and incubation for 4 h at 371C before 15% SDS-PAGE as above and detection by the 3E1 antibody. (d) GFP NRG4A1 in the absence (lane1) and presence (lane 2) of PNGase F, GFP NRGA2 in the absence (lane 3) and presence (lane 4) of PNGase F. (e) 10 mM galardin (and MG-132 as above) was added to Cos-7 cells transfected with either GFP NRG4A1 (lane 2) or GFP NRG4A2 (lane 3) (0.1% serum) for 96 h before 15% SDS-PAGE and detection with the 3E1 GFP antibody. Harari et al., 1999 ) also stimulated phosphorylation of a similar species (Figure 4a, lane 4) .
It has been demonstrated that NRG1 can elicit neuronal outgrowth in PC-12 HER4 cells (a cell line derived from a rat adrenal medullary pheochromocytoma and stably transfected with HER4, Vaskovsky et al., 2000) . On addition of the Con A eluate (from NRG4A1-GFP transfected cells) to PC-12 HER4 cells, neurite outgrowth was observed by 72 h but not on the addition of the eluate from untransfected cells (Figure 4b ). Concentrated conditioned medium from NRG4A1-GFP transfected cells, which had been treated with galardin failed to stimulate neurite outgrowth (Figure 4b) indicating that shedding was a result of proteolytic cleavage. Chemically synthesized and refolded NRG4A1 was used as a positive control for neurite outgrowth. To show directly that a glycosylated fragment that contained the anti-127 epitope was present in the conditioned media, Con A affinity chromatography was carried out on NRG4A1-GFP conditioned medium. Western blotting with the anti-127 antibody detected a single band of approximately 8 kDa, which represents a glycosylated cleaved fragment of NRG4A1 (Figure 4c , lane 1). The presence of NRG4A1 in the conditioned media was not due to cell lysis of the transiently transfected cells as no higher molecular weight species was detected running at the same position as the detergent solubilized full-length, GFP-tagged form (Figure 4c, lane 6) . No proteins were detected in a control experiment using conditioned media from untransfected cells (data not shown).
In summary, these data reveal that in spite of lacking a hydrophobic N-terminal signal sequence, NRG4A1 and A2 are transported to the cell surface as glycosylated peptides and that shedding of a biologically active ligand occurred as a consequence of proteolytic cleavage probably by a TACE/ADAM type protease. We show here that an EGF-like ligand is glycosylated at an asparagine residue within the EGF domain. Inspection of the three-dimensional structure of TGF-a bound to the EGF receptor (Garrett et al., 2002) shows that the equivalent residue to the asparagine in the glycosylation site of NRG4 is exposed on the surface and not buried in the interaction site (see Supplementary Figure 1 ) suggesting that this modification should not sterically hinder binding. Indeed it is clear from the results presented above that both glycosylated (Con A purified) and unglycosylated (chemically synthesized) NRG4 are active. A potential N-linked glycosylation site is also found in NRG2 immediately following the first cysteine residue in the EGF domain (Higashiyama et al., 1997) Figure 4 The glycosylated ectodomain of NRG4 A1 promotes neurite extension in PC-12 HER 4 cells and tyrosine phosphorylation of HER 4. A total of 4 ml conditioned media (containing 0.05% FCS) was collected 48 h after transfection of Cos-7 with NRG4A1 green fluorescent protein (GFP) or from untransfected cells as a negative control, concentrated eightfold using a Vivaspin column (MW cut-off 3000 kDa), and MnCl 2 added to give a final concentration of 5 mM. Concanavalin A (Con A) beads were equilibriated into 0.5 M NaCl, 20 mM Tris, pH 7.4, 5 mM MnCl 2 , 5 mM CaCl 2 and incubated with the concentrated conditioned media at 41C for 2 h. The beads were washed into the equlibriation buffer (see above) and incubated for 5 min at 41C in 1.0 M methyl a-D-mannopyranoside glycoproteins. A total of 100 ml of eluted glycoproteins was recovered from the supernatant and 20 ml was added (a) for 5 min at 371C to NIH 3T3 HER 4 cells that were cultured in the same media as Cos-7 cells (see above). The cells were lysed as above and 15% SDS-PAGE was carried out. The blotted samples were probed with the anti phosphotyrosine antibody, PY20. A parallel gel containing the same samples was probed with the HFR-1 monoclonal antibody to detect the HER4 protein. Refolded NRG4A1 peptide (1 Â 10 À6 M) was used as a positive control; (b) for 72 h at 371C to PC-12 HER 4 cells that were cultured to 50% confluency in RPMI, 5% horse serum 10% FCS (Gibco), 2 mM L-glutamine, 50 mg/ml penicillin and 50 mg/ml streptomycin in coverslip dishes as above. Twenty-four hours before the addition of the conditioned media, the culture medium for both cell lines was changed to 0.1% serum. Chemically synthesized and refolded NRG4A1 peptide (1 Â 10 À5 M) was used as a positive control. Panels top to bottom, first row-Con A-eluted conditioned media (CM) from transfected cells, with 10 mM Galardin, and with chemically synthesized and refolded NRG4A1 peptide. Panels top to bottom-second row-matched controls. Scale bar represents 100 mm. (c) Con A chromatography was carried out on 4 ml NRG4A1 GFP-conditioned media, the column was eluted with 1.0 M methyl a D mannopyranoside (lanes 1 and 4) (200 ml fractions were collected) washed with 20 mM Tris, pH 7.4, 0.5 M NaCl (lanes 2 and 5) and 15% SDS-PAGE was carried out (Tastet et al., 2003) . The fractions were immunoblotted and probed with the anti-127 (lanes 1-3) or anti-GFP antibody (3E1) (lanes 4-6). A protein of approximately 8 kDa was observed in the eluate (lane 1) which was a similar size to the chemically synthesized NRG4A1 peptide (residues 4-46) (lane 3). No GFP-fused protein was observed in the eluate (lane 4). Full-length NRG4A1 GFP was used as a positive control (lane 6).
